Market cap
$4 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.4
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | -- | -- | 58.02 | 20.43 | -201.67 |
| Net Profit | 2.39 | -129.52 | -48.05 | 10.37 | 10.28 |
| EPS | -- | -- | -- | -- | -- |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-23 | Dec-22 |
| EBIT-Margin
| -- | -215.41 | -- | -- | -- |
| Net Margin
| -- | -8,000.42 | -- | -- | -- |
| Return on equity
| -144.30 | -201.06 | -268.87 | -29.12 | -78.83 |
| Return on Capital
| -123.58 | -130.01 | -- | -28.92 | -78.23 |
| Return on Assets
| -109.47 | -110.95 | -59.11 | -22.60 | -71.36 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.00 | 0.01 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
MyMD Pharmaceuticals (MYMD)
|
--
|
-28.92
|
-78.23
|
-263.59
|
-231.29
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-268.87
Lower than Peers by 228.54
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
MyMD Pharmaceuticals (MYMD)
|
-268.87
|
-29.12
|
-78.83
|
-324.96
|
-521.20
|
|
Peer Median
|
-40.33
|
--
|
--
|
--
|
--
|
ROA
-59.11
Lower than Peers by 27.86
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
MyMD Pharmaceuticals (MYMD)
|
-59.11
|
-22.60
|
-71.36
|
-234.45
|
-184.74
|
|
Peer Median
|
-31.24
|
--
|
--
|
--
|
--
|
EBIT Margin
--
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
MyMD Pharmaceuticals (MYMD)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-82.60
|
--
|
--
|
--
|
--
|
Net Margin
--
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
MyMD Pharmaceuticals (MYMD)
|
--
|
--
|
--
|
--
|
-8,000.42
|
|
Peer Median
|
-91.30
|
--
|
--
|
--
|
--
|
Revenue Growth
--
--
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
MyMD Pharmaceuticals (MYMD)
|
--
|
--
|
--
|
--
|
-1.00
|
|
Peer Median
|
54.03
|
--
|
--
|
--
|
--
|
EBIT Growth
58.02
Higher than Peers by 59.04
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
MyMD Pharmaceuticals (MYMD)
|
58.02
|
-119.09
|
46.95
|
-203.64
|
-179.30
|
|
Peer Median
|
-1.02
|
--
|
--
|
--
|
--
|
Net Profit Growth
-48.05
Lower than Peers by 40.52
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
MyMD Pharmaceuticals (MYMD)
|
-48.05
|
73.53
|
49.42
|
-179.78
|
-174.67
|
|
Peer Median
|
-7.53
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
MyMD Pharmaceuticals (MYMD)
|
--
|
0.00
|
0.01
|
0.01
|
-0.79
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
MyMD Pharmaceuticals (MYMD)
|
--
|
0.00
|
0.00
|
0.00
|
-0.10
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
2.48
Lower than Peers by 3.33
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
MyMD Pharmaceuticals (MYMD)
|
2.48
|
1.17
|
1.95
|
12.18
|
0.06
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
2.48
Lower than Peers by 3.21
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
MyMD Pharmaceuticals (MYMD)
|
2.48
|
--
|
--
|
--
|
0.70
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-15.40
Lower than Peers by 13.31
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
MyMD Pharmaceuticals (MYMD)
|
-15.40
|
--
|
-178.90
|
-47.35
|
-7.96
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
MyMD Pharmaceuticals (MYMD)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
19.01
|
--
|
--
|
--
|
--
|
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
MyMD Pharmaceuticals (MYMD)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
MyMD Pharmaceuticals (MYMD)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
MyMD Pharmaceuticals (MYMD)
|
--
|
--
|
--
|
--
|
-8,099.14
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
MyMD Pharmaceuticals (MYMD)
|
--
|
--
|
--
|
--
|
14,888.25
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
MyMD Pharmaceuticals (MYMD)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Book Value
0.44
Lower than Peers by 4.89
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
MyMD Pharmaceuticals (MYMD)
|
0.44
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.33
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
MyMD Pharmaceuticals (MYMD)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-0.03
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
MyMD Pharmaceuticals (MYMD)
|
-0.03
|
0.28
|
0.31
|
0.40
|
1.54
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
4
Lower than Peers by 137
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
MyMD Pharmaceuticals (MYMD)
|
4
|
--
|
--
|
--
|
--
|
|
Peer Median
|
142
|
--
|
--
|
--
|
--
|